Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Efficacy of DAA Therapy for HCV in Older Adults

J Am Geriatr Soc; ePub 2018 May 25; Mazzarelli, et al

Direct-acting antiviral (DAA) therapy is highly efficacious for the treatment of hepatitis C virus (HCV) infection in older adults; however, those aged ≥75 years are more likely to have clinically significant pretreatment drug-drug interactions (DDIs) and experience adverse events (AEs) during therapy. This according to a retrospective review between June 2014 and January 2017 that included individuals aged ≥65 years treated with DAA therapy for HCV during the study period (n=113) divided into 2 cohorts: aged 65 to 74 years (n=88) and aged ≥75 years (n=25). DDIs, AEs, and rates of sustained virologic response (SVR) with DAA therapy were assessed. Among the findings:

  • SVR rate was 97.7% in those aged 65 to 74 years and 95.8% in those aged ≥75 years.
  • Individuals aged ≥75 years were more likely to be taking >2 medications per day for chronic conditions and more likely to have clinically significant DDIs necessitating cessation or adjustment of medications before inauguration of DAA therapy.
  • Those aged ≥75 years were also more likely to experience an AE during therapy.


Mazzarelli C, Considine A, Childs K, et al. Efficacy and tolerability of direct-acting antivirals for hepatitis C in older adults. [Published online ahead of print May 25, 2018]. J Am Geriatr Soc. doi:10.1111/jgs.15392.

This Week's Must Reads

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

Antibiotic Use Among US Older Adults, BMJ; ePub 2018 Jul 27; Olesen, Barnett, et al

Healthy Behaviors & Reduced Risk of Obesity , Mayo Clin Proc; ePub 2018 Jul 27; Shook, et al

Modifiable Risk Factors in New BP Categories, Am J Med; ePub 2018 Jul 26; Gu, Yue, et al

Psychological Screening for Youth with Abdominal Pain, Pediatrics; ePub 2018 Jul 25; Cunningham, et al

Must Reads in Hepatitis

Efficacy of Glecaprevir/Pibrentasvir in Chronic HCV, Clin Gastroenterol Hepatol; ePub 2018 Jul 15; Flamm, et al

Disparities in HCV Screening Among Baby Boomers, Am J Infect Control; ePub 2018 Jul 15; Nili, et al

Chronic Liver Disease Mortality in the US, Gastroenterology; ePub 2018 Jul 15; Kim, et al

Diabetes and Fibrosis Progression in HCV Patients, Dig Liver Dis; ePub 2018 Jul 17; Yen, et al

Incidence and Spontaneous Clearance of HCV in PWID , J Viral Hepat; ePub 2018 Jul 11; Kåberg, et al